Discovery of a Novel Class of Phosphodiesterase 10A Inhibitors and Identification of Clinical Candidate 2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the Treatment of Schizophrenia††Coordinates...

MLA

Patrick R. Verhoest, et al. “Discovery of a Novel Class of Phosphodiesterase 10A Inhibitors and Identification of Clinical Candidate 2-[4-(1-Methyl-4-Pyridin-4-Yl-1H-Pyrazol-3-Yl)-Phenoxymethyl]-Quinoline (PF-2545920) for the Treatment of Schizophrenia††Coordinates..” Journal of Medicinal Chemistry, vol. 52, no. 16, Aug. 2009, pp. 5188–96. EBSCOhost, https://doi.org/10.1021/jm900521k.

APA

Patrick R. Verhoest, Douglas S. Chapin, Michael Corman, Kari Fonseca, John F. Harms, Xinjun Hou, Eric S. Marr, Frank S. Menniti, Frederick Nelson, Rebecca O’Connor, Jayvardhan Pandit, Caroline Proulx-LaFrance, Anne W. Schmidt, Christopher J. Schmidt, Judith A. Suiciak, & Spiros Liras. (2009). Discovery of a Novel Class of Phosphodiesterase 10A Inhibitors and Identification of Clinical Candidate 2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the Treatment of Schizophrenia††Coordinates.. Journal of Medicinal Chemistry, 52(16), 5188–5196. https://doi.org/10.1021/jm900521k

Chicago

Patrick R. Verhoest, Douglas S. Chapin, Michael Corman, Kari Fonseca, John F. Harms, Xinjun Hou, Eric S. Marr, et al. 2009. “Discovery of a Novel Class of Phosphodiesterase 10A Inhibitors and Identification of Clinical Candidate 2-[4-(1-Methyl-4-Pyridin-4-Yl-1H-Pyrazol-3-Yl)-Phenoxymethyl]-Quinoline (PF-2545920) for the Treatment of Schizophrenia††Coordinates..” Journal of Medicinal Chemistry 52 (16): 5188–96. doi:10.1021/jm900521k.